Signaturefd LLC Has $370,000 Holdings in Hologic, Inc. $HOLX

Key Points

• Signaturefd LLC increased its holdings in Hologic, Inc. by 196.1%, owning a total of 5,683 shares valued at $370,000 as of the second quarter.
• CEO Stephen P. Macmillan sold 138,358 shares, representing a 10.08% decrease in his holdings, valued at approximately $9.3 million post-sale.
• Hologic reported earnings exceeding analysts' expectations, with a net margin of 13.79% and projected Q4 2025 EPS guidance of $1.090-1.120.

Signaturefd LLC increased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 196.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,683 shares of the medical equipment provider's stock after acquiring an additional 3,764 shares during the period. Signaturefd LLC's holdings in Hologic were worth $370,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc boosted its holdings in Hologic by 1,864.3% in the 1st quarter. Versant Capital Management Inc now owns 1,375 shares of the medical equipment provider's stock worth $85,000 after buying an additional 1,305 shares during the period. Rhumbline Advisers boosted its holdings in Hologic by 5.1% in the 1st quarter. Rhumbline Advisers now owns 535,348 shares of the medical equipment provider's stock worth $33,068,000 after buying an additional 25,822 shares during the period. Czech National Bank boosted its holdings in Hologic by 2.3% in the 1st quarter. Czech National Bank now owns 51,538 shares of the medical equipment provider's stock worth $3,184,000 after buying an additional 1,176 shares during the period. Procyon Advisors LLC bought a new position in Hologic in the 1st quarter worth approximately $692,000. Finally, Clean Yield Group boosted its holdings in Hologic by 15.9% in the 1st quarter. Clean Yield Group now owns 52,909 shares of the medical equipment provider's stock worth $3,268,000 after buying an additional 7,263 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.88% of the company's stock.

Hologic Stock Down 0.7%

HOLX opened at $67.04 on Thursday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The company has a market capitalization of $14.91 billion, a PE ratio of 27.82, a PEG ratio of 2.45 and a beta of 0.63. The firm's 50 day simple moving average is $66.90 and its two-hundred day simple moving average is $63.00.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the company posted $1.06 EPS. The business's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and boosted their price target for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Mizuho set a $75.00 price objective on shares of Hologic in a report on Thursday, July 31st. Morgan Stanley lifted their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Evercore ISI lifted their price objective on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Finally, Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, Hologic currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.38.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.